Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Sagimet Biosciences Inc.NASDAQ: SGMT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$10.65M, compared with -$18.18M a year earlier. Trailing-twelve-month EBITDA was -$46.14M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$38.91M (+23.8%) for the fiscal year ending Dec 2026, a step up from the -12.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.65M+12.6% QoQ
- Last fiscal yearDec 2025
- -$51.04M-12.0% YoY
- LTMMar 2026
- -$46.14M+19.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +41.4% | — | — |
| 1 year | -12.0% | +23.8% | +35.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (51.04M) USD
- Year-over-year change
- -12.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (51.04M) | -12.0% |
| FY2024 | 2024-12-31 | (45.57M) | -63.5% |
| FY2023 | 2023-12-31 | (27.88M) | +8.2% |
| FY2022 | 2022-12-31 | (30.37M) | -24.2% |
| FY2021 | 2021-12-31 | (24.44M) | — |
EBITDA vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 EBITDA of -$46.14M is the 2nd highest of the 11 companies compared; the peer median is -$73.95M.
- Its year-over-year change of +19.2% is the 2nd highest of 11, against a peer median of -18.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$46.14M | +19.2% | — | — |
| LTM Mar 2026 | -$50.86M | -14.6% | — | — | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$67.53M | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M | -21.4% | — | — |
| LTM Mar 2026 | -$79.77M | -33.1% | — | 3956.7% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Mar 2026 | -$164.87M | -697.5% | — | 2873.3% | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| Peer median (excluding SGMT) | -$73.95M | -18.0% | — | 282.7% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Selling, General & Admin | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Operating Expenses | 23.72M | 31.06M | 32.74M | 54.45M | 56.89M |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| EBITDA | (24.44M) | (30.37M) | (27.88M) | (45.57M) | (51.04M) |
| EBITDA Margin | — | — | -1393.8% | — | — |
| Operating Income | (23.72M) | (31.06M) | (30.74M) | (54.45M) | (56.89M) |
| Operating Margin | — | — | -1537.0% | — | — |
| Interest Income | 26K | 553K | 2.86M | 8.89M | 5.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (723K) | 556K | 2.86M | 8.89M | 5.85M |
| Income Before Tax | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Pre-Tax Margin | — | — | -1393.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Net Margin | — | — | -1393.8% | — | — |
| EPS (Basic) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| EPS (Diluted) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| Weighted Avg Shares | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Weighted Avg Shares (Diluted) | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.